8月首个交易日，三大指数小幅收跌，截至收盘，沪指跌0.37%，深成指跌0.17%，创业板指跌0.24%。 沪深两市全天成交额1.60万亿元，较上个交易日缩量3377亿元。全市场超3300家个股上涨。板块方面， 中药、电力设备、AI智能体、造纸等板块涨幅居前，中船系、民爆、PCB、CPO等板块跌幅居前。 （图源：南财金融终端） 回顾7月，A股三大指数震荡走高，沪指一度站上3600点。当月沪指涨3.74%，深证成指涨5.20%，创业 板指涨8.14%。在行业方面，申万31个一级行业中有28个行业实现了上涨，涨幅前三分别是：钢铁 （16.76%）、医药生物（13.93%）、建筑材料（13.36%）；在3个下跌行业中，银行（-1.95%）跌幅 最大，公共事业（-0.77%）、交通运输（-0.22%）跟随其后。 8月接下来还会演绎怎样的行情？机构看好的"金股"有哪些？又给出了哪些配置建议？接下来，我们一 起来看看。 一、流动性起到明显支撑作用，市场震荡蓄势后有望上行 据不完全统计，目前已有20余家券商发布了8月投资组合和最新市场观点。 纵观这些报告，多家机构认为在流动性支撑下，A股市场在震荡蓄势后有望上行。 国联民生证 ...

7月A股震荡走强，结构性机会不断涌现，私募机构调研热情高涨，为后市布局积极"探路"。 第三方机构最新监测数据显示，7月共有657家私募证券管理人参与A股上市公司调研，覆盖358只个 股，合计调研1763次。从行业到个股，科技成长领域成为调研焦点。 德福科技成"人气王" 7月私募调研呈现明显的头部集中效应。第三方机构私募排排网监测数据显示，7月52只个股获得不少于 10次调研，其中前十名个股（含并列排名，下同）均被调研至少24次。 电力设备龙头德福科技以74次调研领先，远超其他个股，该股在7月吸引了聚鸣投资、睿郡资产等众多 百亿私募扎堆关注。另一只电力设备股孚能科技以42次调研位居第二。通信行业的新易盛（34次）、汽 车行业的涛涛车业（32次）以及医药生物行业的海正药业（27次）进入前五。此外，农林牧渔、电子、 环保、机械设备等行业均有个股跻身前十。 从股价表现来看，7月私募调研十大热门股中，出现多只"月度牛股"。德福科技7月股价累计大涨 73.57%，新易盛、涛涛车业、仕佳光子7月股价均涨逾40%，大禹节水、海正药业7月涨幅均超20%。 行业层面，14个申万一级行业获得不少于30次调研。前十名行业均被调研至少 ...

Core Insights - The pharmaceutical industry is complex, with cyclical fluctuations in raw materials, high-tech characteristics of innovative drugs, and the consumer nature of medical services intertwining, making market predictions and investment management challenging [1] - Jiang Qi, a fund manager at Dongfanghong Asset Management, has developed a precise investment strategy in the pharmaceutical sector through years of industry experience [1] Group 1: Investment Strategy - The core of pharmaceutical investment lies in understanding cyclical fluctuations and long-term trends, which is essential for constructing resilient investment portfolios [2] - Jiang Qi's investment logic emphasizes a "top-down approach to selecting sectors and a bottom-up approach to selecting companies," with policy direction and growth potential as key indicators of sector value [2] - Historical trends show clear sector rotations, with innovative drugs and consumer upgrades becoming the main focus post-2019, and traditional Chinese medicine gaining traction due to policy support from 2022 to 2023 [2] Group 2: Long-term Outlook - Long-term returns in the pharmaceutical industry stem from technological growth, with companies that continuously break through technical barriers and create clinical value being the most resilient [3] - A diversified portfolio is necessary to navigate market volatility, balancing growth stocks' explosive potential with the defensive strength of undervalued assets [3] Group 3: Innovation Focus - The key variable for investment success in the current phase is innovative drugs, which have transitioned from quantitative accumulation to qualitative breakthroughs since 2015 [4] - Investment in innovative drugs should move beyond traditional valuation frameworks, focusing on global competitiveness, clinical value, and commercialization potential [4] - Recent strategic collaborations between Chinese innovative drug companies and multinational pharmaceutical firms highlight the increasing credibility of Chinese clinical data and global competitiveness [4] Group 4: Future Projections - By the second half of 2025, the direction of the innovative drug industry is expected to become clearer, supported by technological advancements and improved clinical resources [5] - The upcoming reforms in commercial health insurance are anticipated to significantly impact the industry, similar to the 2015 clinical trial data verification initiative [5] - The period from 2025 to 2029 is projected to be the first phase of harvest for the innovative drug sector, following a decade of investment from 2015 to 2024 [5] Group 5: Value Preservation - The ultimate goal of investment is to focus on long-term value rather than short-term gains, especially in the face of high uncertainty in the pharmaceutical industry [6] - Risk control is crucial, with a focus on left-side positioning and in-depth research to uncover opportunities during industry downturns [7] - The long-term value anchor remains the clinical value and growth potential created by companies, addressing unmet health needs through innovation and service upgrades [7]

Core Viewpoint - The A-share market is experiencing a positive trend with various sectors showing strength, particularly in photovoltaic, liquid cooling servers, and logistics, while military and sports sectors are facing declines. Analysts suggest that the market is entering a medium to long-term slow bull phase, presenting opportunities for investors during market pullbacks [1][6]. Sector Summaries Liquid Cooling Server Sector - The liquid cooling server concept continues to show strength, with companies like Chuanrun Co. and Dayuan Pump Industry reaching their upper price limits. The global leader in liquid cooling, Viant Technology, reported better-than-expected revenue and profit for Q2 2025, with organic orders up approximately 11% year-over-year and backlog orders increasing to $8.5 billion [2]. Express Logistics Sector - The express logistics sector is collectively strong, with companies such as Shentong Express and Yunda Holdings hitting their upper price limits. A recent meeting by the State Post Bureau focused on addressing "involution" competition and improving service quality in rural areas, which is expected to promote high-quality development in the industry [3]. Institutional Perspectives - Huaxi Securities predicts that A-shares may challenge 2024 highs in the second half of the year, driven by improved corporate earnings and increased market participation from retail investors. The "anti-involution" measures are expected to enhance investor sentiment [4]. - Huatai Securities believes that short-term corrections will contribute to a more stable market environment, with upcoming mid-year earnings reports likely to draw investor attention to performance certainty and valuation alignment [5]. - Dongfang Securities asserts that the market has entered a medium to long-term slow bull phase, with reduced volatility and healthy rotation of market hotspots, suggesting that significant pullbacks present buying opportunities [6].

Market Overview - On July 31, the A-share market opened lower and experienced wide fluctuations, with the Shanghai Composite Index finding support around 3580 points[2] - The Shanghai Composite Index closed at 3573.21 points, down 1.18%, while the Shenzhen Component Index closed at 11009.77 points, down 1.73%[7] - Total trading volume for both markets was 19,621 billion yuan, above the median of the past three years[3] Sector Performance - Strong performers included banking, software development, internet services, and consumer electronics, while coal, steel, energy metals, and shipbuilding sectors lagged[3] - Over 70% of stocks in the two markets declined, with chemical pharmaceuticals, software development, and internet services showing the largest gains[7] Valuation Metrics - The average price-to-earnings (P/E) ratios for the Shanghai Composite and ChiNext indices are 14.81 times and 41.76 times, respectively, indicating a mid-level valuation compared to the past three years[3] - The market is currently in a dual-driven phase of policy and capital, establishing a slow upward trend despite short-term technical adjustment pressures[3] Economic Context - China's economy continues to show moderate recovery, with consumption and investment as core drivers[3] - Long-term capital inflows are increasing, with steady growth in ETF sizes and continuous inflow from insurance funds, providing significant support[3] Investment Recommendations - It is suggested to focus on technology growth and cyclical manufacturing as dual main lines for investment, while also considering high-dividend banks, public utilities, and strategic emerging industries[3] - Short-term market expectations lean towards steady upward fluctuations, with close monitoring of policy, capital, and external market changes advised[3]

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Growth Index rose by 0.03%, while the Sci-Tech 100 Index fell by 0.4%, the Sci-Tech Comprehensive Index decreased by 0.7%, and the Shanghai Sci-Tech Innovation Board 50 Component Index dropped by 1.0% [1] - Industrial Securities indicated that the rotation of sectors and the expansion of market trends reflect an increase in market risk appetite, with various funds actively seeking and exploring underpriced segments within the main lines [1] - The consensus around "technology growth + cyclical" has been continuously solidifying in the market, generating profit effects, while some sub-sectors still have low crowding levels, suggesting that various funds may continue to actively explore detailed opportunities within [1]

券商8月"金股"名单近期陆续出炉。据中国证券报记者不完全统计，截至目前，已有109只A股及港股标 的入围券商8月"金股"名单。 从推荐频次看，"券茅"东方财富最受青睐，共获得3家券商推荐，大金重工、东鹏饮料、沪电股份等8家 公司均获得2家券商推荐。 券商认为，8月A股市场或呈现指数震荡缓升但波动加大的格局，投资者既需重视景气支撑或业绩兑现 超预期的基本面机会，也要重视事件主题催化的估值性机会；对于港股市场，未来或将继续震荡上行， 配置上继续看好科技成长及高股息占优的"哑铃"策略。 东方财富8月最受券商关注 7月31日，康辰药业股价上涨逾2%，再创历史新高，7月累计涨幅为106.74%，在券商推荐的279只7 月"金股"中居于首位，其入围了平安证券7月月度"金股"组合。博瑞医药、苑东生物、东山精密、鼎通 科技、统联精密7月累计涨幅均在50%以上，作为7月月度"金股"，分别获得东吴证券、平安证券、长江 证券、财信证券、东兴证券的推荐。 建议关注科技、先进制造等方向 展望A股市场8月表现，多家机构持相对积极态度，判断结构性行情有望延续，但波动可能加大。 中国银河认为，A股市场预计将在政策预期利好、经济温和复苏、中报 ...

创业板ETF天弘（159977）紧密跟踪创业板指数（399006.SZ），该指数是深交所多层次资本市场的核 心指数之一，由最具代表性的100家创业板上市企业股票组成，反映创业板市场层次的运行情况。创业 板指数新兴产业、高新技术企业占比高，成长性突出。截至最新，创业板指前十大指数中包含宁德时 代、东方财富、汇川技术、中际旭创、迈瑞医疗、新易盛、胜宏科技等。创业板ETF天弘（159977）同 时配置场外创业板ETF联接基金（A:001592；C:001593）。 中原证券在7月29日的研报中指出，当前上证综指与创业板指数的平均市盈率分别为14.78倍、41.32倍， 处于近三年中位数平均水平，适合中长期布局。当前A股市场已进入政策与资金双轮驱动阶段，慢涨格 局基本确立。配置上建议关注科技成长+周期制造双主线，同时继续关注高股息银行、公用事业及战略 新兴产业。预计短期市场以稳步震荡上行为主，仍需密切关注政策面、资金面以及外盘的变化情况。短 线建议关注医药、通信设备、航天航空以及半导体等行业的投资机会。 7月31日，A股三大指数走势分化，创业板指盘中一度涨超1%，CPO概念再度活跃，中际旭创、新易盛 盘中股价再创历史 ...

Group 1: Fund Analysis - The public FOF fund scale increased in Q2 2025, with significant growth from major fund companies like Southern, Dongfanghong, and Bosera, while Xingsheng Global remains the largest [7][9] - Over 90% of FOF funds recorded positive returns, with Shenwan Lingshin Zhihua's stable allocation strategy achieving the highest performance over three months [7][10] - Fund managers are optimistic about the equity market, focusing on structural opportunities rather than index performance, with technology growth expected to be a key theme [7][13] Group 2: Macroeconomic Insights - The July Politburo meeting emphasized the need for detailed implementation of macroeconomic policies to boost consumption and investment, while ensuring employment and price stability [15][16] - China's GDP grew by 5.3% year-on-year in the first half of 2025, exceeding the growth target, with the IMF raising China's economic growth forecast for 2025 to 4.8% [15][16] - The meeting highlighted the importance of maintaining liquidity and supporting sectors like technology innovation and small businesses to stimulate economic growth [16][17] Group 3: Fixed Income Market - In June 2025, the total bond custody volume increased slightly, with insurance companies increasing their holdings in local government bonds while trusts reduced their exposure to exchange-traded bonds [22][24] - Commercial banks and broad-based funds increased their holdings in interest rate bonds, while reducing their investments in certificates of deposit [24][26] - The bond market is expected to face redemption pressure, but the attractiveness of the bond market may support demand from insurance and banking sectors [26] Group 4: Company-Specific Insights - WuXi AppTec's H1 2025 revenue reached 20.8 billion yuan, a 20.64% increase, with net profit growing by 101.92% due to asset disposals [28][30] - The company anticipates revenue growth of 10.3%, 15.3%, and 15.3% for 2025, 2026, and 2027, respectively, with net profit expected to grow significantly in 2025 [30][31] - WuXi's strong order backlog of 56.69 billion yuan reflects a 37.2% year-on-year increase, indicating robust demand across its business segments [28][30] Group 5: Communication Sector - Weisheng Information reported stable performance in H1 2025, with revenue of 1.368 billion yuan, up 11.88%, and net profit of 305 million yuan, up 12.24% [32][34] - The company has emphasized shareholder returns through cash dividends and share buybacks, maintaining a commitment to a 40% dividend payout ratio over the next five years [34]

7月30日，A股主要指数涨跌不一，沪指涨0.17%报3615点，深证成指跌0.77%，创业板指跌1.62%。全市场超3500股下跌。 具体来看： 影视院线板块领涨，幸福蓝海20CM涨停，金逸影视、慈文传媒、北京文化、上海电影、光线传媒、中国电影等跟涨。 | 代码 名称 | | 现价 | 裸跌 | 米幅 | | --- | --- | --- | --- | --- | | 300528 幸福蓝海 | | 25.32 | | +4.22 +20.00% | | GOGZOD | 金逸影视 | 10.52 | +0.96 | +10.04% | | 002343 慈文传媒 | | 8.58 | +0.78 | +10.00% | | 000802 北京文化 | | 6.11 | +0.51 | +9.11% | | 601595 上海电影 | | 36.04 | +2.28 | +6.75% | | 300251 | 光线传媒 | 20.55 | +0.71 | +3.58% | | 600977 中国电影 | | 14.75 | +0.40 | +2.79% | | 600715 文投控股 | | 2.41 | ...